Afexa Life Sciences Inc.
TSX : FXA

Afexa Life Sciences Inc.

October 30, 2009 08:00 ET

Boost Your Immune System Year Round-That's the Goal of Immunity-FX™, a New Product Launched by the Maker of Cold-FX®

Nation-Wide Rollout of Immunity-FX™ Begins Tomorrow at Major Health/ Lifestyle Show in Toronto

TORONTO, ONTARIO--(Marketwire - Oct. 30, 2009) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) maker of COLD-FX today announced plans to launch a sister product - IMMUNITY-FX - for year round immune health support. The new immune system booster will debut at Toronto's health and lifestyle expo, the "Zoomer Show" Oct 31 - Nov 1.

IMMUNITY-FX was designed as a daily immune booster to help consumers stay healthy. It's a special formulation to help the immune system fight germs and pathogens that are foreign to the body. It's the only product of its kind and contains two immune strengthening ingredients - CVT-E002, the active ingredient in COLD-FX which is a clinically proven proprietary extract from the North American ginseng plant, and Reishi mushroom, another natural product recognized world-wide for its effect in strengthening the immune system. Scientific research has uncovered the unique molecular mechanisms of both these ingredients which work together in a complementary manner to stimulate and balance the immune system.

COLD-FX co-discoverer and Afexa Life Sciences Inc. Chief Scientific Officer Dr. Jacqueline Shan says, "IMMUNITY-FX has been in development for a number of years using ChemBioPrint, our proprietary standardization technology which identifies and isolates active ingredients in organic mixtures and ensures consistency and efficacy from batch to batch. IMMUNITY-FX helps strengthen the body's natural defences which are important for improving overall health and wellness and maintaining health when faced with periods of stress. This product is our answer to requests from pharmacists and consumers for a year round daily immune booster."

Dr. Shan adds, "The immune system is a marvellous, complex system. It can recognize and remember millions of different enemies, and it can produce millions of defensive cells to engage in search-and-destroy missions against attacks by foreign invaders. Having a strong immune system is particularly important these days. Our laboratory and clinical research on the core ingredient of IMMUNITY-FX suggests it can enhance the immune system's effectiveness by directly interacting with specific receptor molecules, such as Toll-like receptors, which function as the immune system's 'sentinels' calling for a response when it's under attack. These receptors are critical to the immune function, detecting intruders and triggering protective immune responses."

"We've always been committed to prevention," Dr. Shan continues. "Prevention is better than a cure. The goal should be to enhance the body's own self-defence and self-healing process, to optimize prevention and accelerate recovery. We feel the addition of IMMUNITY-FX to our immune strengthening family of products, which includes COLD-FX, gives consumers added choices for improved health protection and well-being year round."

IMMUNITY-FX is now on the shelves of leading pharmacies, retailers and natural health products stores across Canada. IMMUNITY-FX is the first of two products Afexa plans to roll out during this fiscal year.

About Afexa Life Sciences Inc.

Afexa Life Sciences Inc. (formerly CV Technologies) founded in 1992 strives to transform people's lives to be healthier and happier by focusing on prevention and recovery through the use of evidence-based naturally-derived health products. The Company's lead product COLD-FX® strengthens the immune system and is widely used as a leading over the counter remedy ("OTC") for helping to prevent and relieve cold and flu inflections.

Forwarding looking Statement

This news release contains certain forward-looking statements and information within the meaning of applicable securities laws, which reflect current expectations of the management of Afexa Life Sciences Inc. (the "Company") regarding future events or the Company's future performance, including, without limitation, statements relating to the timing and/or initiation of clinical trials, clinical trial results, the introduction of new products, associated regulatory clearances, economic or financial trends or expectations, financing, acceptance of the Company's products in the marketplace and the hiring or retention of personnel. Forward-looking statements are often, but not always, identified by the use of words such as "expect", "anticipate", "seek", "aim", "continue", "estimate", "objective", "ongoing", "may", "will", "would", "project", "predict", "potential", "could", "should", "might", "believe", "plan", "target", "intend" and similar expressions. All statements other than statements of historical fact contained in this news release may be forward-looking statements. The forward-looking information included in this document does not guarantee future performance and should not be unduly relied upon. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including, without limitation, the impact of competition, the incidence of cold and flu, consumer confidence and spending levels, general economic conditions, interest and currency exchange rates, unseasonable weather patterns, the cost and availability of capital and grants/funding, product development uncertainties, labour market challenges, consumer acceptance of COLD-FX in other markets and consumer acceptance of IMMUNITY-FX. The Company believes that the expectations and assumptions reflected in the forward-looking information contained herein are reasonable but no assurance can be given that these expectations and assumptions are correct or that that the results, performance or achievements expressed in, or implied by, forward-looking statements herein will occur, or if they do, that any benefits may be derived from them. The Company can give no assurance that new product development initiatives will lead to new product commercialization. The Company assumes no duty to update or revise forward looking information, except as may be required pursuant to applicable laws. All forward-looking information is expressly qualified in its entirety by this cautionary statement. Further information regarding risks and uncertainties relating to the Company and its securities can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at www.sedar.com. The Company claims exemption under U.S. SEC Rule 12g3-2(b).

Contact Information